Nurix Therapeutics, Inc.
NRIX
$25.96
$0.080.31%
NASDAQ
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 44.64% | -53.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 44.64% | -53.95% | |||
| Cost of Revenue | 4.18% | 1.34% | |||
| Gross Profit | -0.93% | -12.15% | |||
| SG&A Expenses | 6.74% | 7.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.56% | 2.15% | |||
| Operating Income | -1.85% | -11.31% | |||
| Income Before Tax | -3.02% | -11.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.71% | -11.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.71% | -11.45% | |||
| EBIT | -1.85% | -11.31% | |||
| EBITDA | -1.83% | -10.69% | |||
| EPS Basic | -1.77% | 3.72% | |||
| Normalized Basic EPS | -2.08% | 3.72% | |||
| EPS Diluted | -1.77% | 3.72% | |||
| Normalized Diluted EPS | -2.08% | 3.72% | |||
| Average Basic Shares Outstanding | 0.92% | 15.76% | |||
| Average Diluted Shares Outstanding | 0.92% | 15.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||